ERBB2 and breast cancer: In the subgroup of HER2-/HR + breast cancer receiving neoadjuvant chemotherapy, pCR patients with cN+ at baseline had a higher risk for a DFS event than cN0 patients (hazard ratio 2.24, 95%CI 1.18–4.25, p = 0.013; multivariate Cox regression analyses) but none of the other potential risk factors significantly increased the risk for a DDFS or OS event.